"I am pleased to join the ANAVEX team at such a critical juncture in the company's growth and to be leading the development of a group of novel drug compounds with disease-modifying potential," said Dr. Goundis. "ANAVEX's approach to treating diseases is unique and unmatched in the industry. Our drug candidates have the potential to be safer and more effective than medications currently on the market because they aim to modify and treat the underlying causes, as opposed to just the symptoms, of Alzheimer's, epilepsy and various types of cancer.
Prior to joining ANAVEX, Dr. Goundis spent six years in various management roles with his most recent as Managing Director at Speedel Experimenta, the late-stage research unit of public biopharmaceutical company Speedel AG. During his tenure, Dr. Goundis led the successful development of SPP100 from Phase I through Phase IIb clinical trials, at which time Novartis exercised its license-back option. Today, SPP100 is sold in the United States under the trade name Tekturna and in Europe under the name Rasilez to treat hypertension. In addition, Dr. Goundis spent several years with lead responsibility for the company's entire development portfolio, including compounds in Phases I, II and III.
Dr. Goundis' background also includes director-level positions with The
Medicines Company, where he was responsible for leading and managing the
CNS business unit, and Roche, where he managed projects across a variety of
|SOURCE Anavex Life Sciences Corp.|
Copyright©2008 PR Newswire.
All rights reserved